Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...
The New England Journal of Medicine

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
Science Daily

This powerful drug combo cuts prostate cancer deaths by 40%

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
The American Journal of Managed Care

Enzalutamide Combo Improves OS in Prostate Cancer Without Sacrificing Quality of Life: Stephen Freedland, MD

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...
UroToday

ESMO 2025: ARAAT: Real-World PSA Response with Darolutamide or Abiraterone in mHSPC Triplet Therapy

The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...